Immune checkpoint blockade in glioma

Sherise D. Ferguson, Shiao Pei Weathers, Amy B. Heimberger

Research output: Chapter in Book/Report/Conference proceedingChapter


Immunotherapeutic strategies have had a profound impact on cancer patient outcome. As such, targeting the immune checkpoints in particular has gained widespread acceptance as a viable immune therapy for several malignancies. Despite the success of immune checkpoint inhibitors in extending the survival of patients with melanoma or lung cancer, the use of checkpoint blockade in the treatment of glioma is far from established. The goal of this review is to outline the current data on the use of checkpoint inhibition for the treatment of glioma, with additional emphasis on oligodendroglioma.

Original languageEnglish (US)
Title of host publicationOligodendroglioma
Subtitle of host publicationClinical Presentation, Pathology, Molecular Biology, Imaging, and Treatment
Number of pages10
ISBN (Electronic)9780128131589
ISBN (Print)9780128131596
StatePublished - Jan 1 2019


  • Checkpoint
  • Glioma
  • Immunotherapy
  • Oligodendroglioma

ASJC Scopus subject areas

  • General Neuroscience


Dive into the research topics of 'Immune checkpoint blockade in glioma'. Together they form a unique fingerprint.

Cite this